Related Experiment Videos
Summary
Serum carcinoembryonic antigen (CEA) levels can help monitor head and neck cancer treatment response. While not predicting survival, CEA levels decrease with tumor regression during treatment, indicating its adjunctive value.
Area of Science:
- Oncology
- Biomarkers
- Head and Neck Cancer Research
Background:
- Carcinoembryonic antigen (CEA) is a biomarker investigated for various cancers.
- Head and neck squamous cell carcinomas are a significant group of malignancies.
Purpose of the Study:
- To evaluate the role of serum CEA levels in patients with head and neck squamous carcinoma.
- To determine if CEA levels correlate with tumor stage, treatment response, and survival.
Main Methods:
- Serum CEA levels were measured in 439 head and neck cancer patients, 154 healthy smokers, and 122 non-smokers.
- CEA levels were analyzed in relation to clinical stage, treatment (resection, irradiation), and survival outcomes.
Main Results:
- Elevated CEA levels were observed in tumor-bearing patients, correlating with clinical stage.
- CEA levels decreased post-resection and during palliative irradiation with tumor regression.
- Irradiation did not cause non-specific CEA elevation.
- CEA levels were similar in tumor-bearing patients, tumor-free treated patients, and smokers when advanced malignancies were excluded.
Conclusions:
- Serum CEA levels are unlikely to predict prognosis in head and neck squamous carcinomas post-therapy.
- Serial CEA monitoring may serve as an adjunctive tool for assessing tumor response to treatment.